MISTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Milestone Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.70−0.01 (-1.02%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
40.8%
51M of 124M shares
Institutional holders
78
6 new, 13 sold out
Net institutional buying
11M
In Q2 2026
Insider trades, 12 months
0 buys · 13 sales
Net sold $1.18M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong | 9,155,168 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Pavaki Capital Management LLC | 9,067,848 | 7.30% | 13G (passive) | Dec 31, 2025 |
| Trails Edge Biotechnology Master Fund, LP | 9,017,880 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Richard Kayne | 8,861,186 | 9.90% | 13G (passive) | Jul 11, 2025 |
| Robert Atchinson | 8,659,064 | 9.99% | 13G (passive) | Sep 30, 2025 |
| Phillip Gross | 8,000,000 | 6.37% | 13G (passive) amendment | Mar 31, 2026 |
| RTW Investments, LP | 12,356,953 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MIST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Pavaki Capital Management LLC | 9,067,848 | 7.28% | $12.15M | +5,000 | 4.24% |
| Rtw Investments, LP | 7,833,336 | 6.29% | $10.50M | +1,502,335 | 0.09% |
| Propel Bio Management, LLC | 7,429,590 | 5.97% | $9.96M | +3,311,269 | 5.21% |
| Point72 Asset Management, L.P. | 5,411,138 | 4.35% | $7.25M | +4,325,455 | 0.01% |
| Simplify Asset Management Inc. | 3,349,379 | 2.69% | $4.49M | +1,842,974 | 0.06% |
| Millennium Management LLC | 3,142,219 | 2.52% | $4.21M | +1,597,894 | 0.00% |
| Kalehua Capital Management LLC | 2,538,474 | 2.04% | $3.40M | New | 1.09% |
| Two Sigma Investments, LP | 2,040,015 | 1.64% | $2.73M | −277,161 | 0.00% |
| Marshall Wace, Llp | 1,797,695 | 1.44% | $2.41M | −146,835 | 0.00% |
| Lion Point Capital, LP | 820,000 | 0.66% | $1.10M | – | 5.26% |
| Toronto Dominion Bank | 750,000 | 0.60% | $1.01M | – | 0.00% |
| Ameriprise Financial Inc | 666,666 | 0.54% | $893.33K | – | 0.00% |
| Boxer Capital Management, LLC | 666,666 | 0.54% | $893.33K | – | 0.07% |
| Morgan Stanley | 635,211 | 0.51% | $851.18K | −88,930 | 0.00% |
| UBS Group AG | 465,403 | 0.37% | $623.64K | −29,505 | 0.00% |
| Boothbay Fund Management, LLC | 462,669 | 0.37% | $619.98K | +293,994 | 0.01% |
| Susquehanna International Group, Llp | 359,895 | 0.29% | $482.26K | −159,151 | 0.00% |
| Aptus Capital Advisors, LLC | 339,450 | 0.27% | $454.86K | +59,200 | 0.00% |
| Guardian Wealth Advisors, LLC / Nc | 339,450 | 0.27% | $454.86K | +59,200 | 0.03% |
| Seven Fleet Capital Management LP | 270,233 | 0.22% | $362.11K | −63,100 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 78 | 51M | 40.8% | 6 / 23 | 23 / 13 | 16M | 5M |
| Q1 2026 | 87 | 40M | 31.7% | 21 / 23 | 19 / 14 | 12M | 8M |
| Q4 2025 | 80 | 35M | 28.1% | 29 / 21 | 9 / 9 | 16M | 15M |
| Q3 2025 | 61 | 34M | 27.4% | 26 / 18 | 4 / 7 | 25M | 3M |
| Q2 2025 | 43 | 12M | 9.5% | 10 / 10 | 9 / 10 | 1M | 1M |
| Q1 2025 | 43 | 12M | 9.5% | 14 / 6 | 11 / 17 | 3M | 16M |
| Q4 2024 | 47 | 25M | 19.7% | 10 / 14 | 14 / 6 | 2M | 6M |
| Q3 2024 | 43 | 29M | 23.0% | 5 / 9 | 10 / 1 | 5M | 4M |
| Q2 2024 | 40 | 32M | 25.6% | 3 / 9 | 7 / 6 | 3M | 4M |
| Q1 2024 | 43 | 33M | 26.5% | 11 / 13 | 7 / 7 | 16M | 1M |
| Q4 2023 | 40 | 19M | 14.9% | 8 / 9 | 10 / 7 | 3M | 4M |
| Q3 2023 | 39 | 20M | 15.7% | 2 / 9 | 14 / 11 | 0M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MIST | Value | % of fund | As of |
|---|---|---|---|---|---|
| Simplify Propel Opportunities ETF | 3,349,379 | 2.69% | $4.49M | 5.81% | Jun 30, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 44,936 | 0.04% | $63.81K | 0.34% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 40,789 | 0.03% | $57.92K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 22,564 | 0.02% | $30.24K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 10,999 | 0.01% | $14.74K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph Oliveto | President and CEO, Director | 446,244 | 0.36% | Apr 20, 2026 |
| David I. Sandoval | GC & Chief Compliance Officer | – | – | Mar 23, 2026 |
| Amit Hasija | CFO & EVP of Corp. Development | 112,093 | 0.09% | Feb 5, 2026 |
| Lorenz Muller | Chief Commercial Officer | 205,406 | 0.16% | Feb 5, 2026 |
| David Bharucha | Chief Medical Officer | 125,426 | 0.10% | Feb 5, 2026 |
| Jeffrey Edward Nelson | Chief Operating Officer | 49,848 | 0.04% | Feb 5, 2026 |
| Stuart Duty | Director | – | – | Jun 12, 2026 |
| Robert James Wills | Director | 65,000 | 0.05% | Jun 12, 2026 |
| Joseph C. Papa | Director | 100,000 | 0.08% | Jun 12, 2026 |
| Seth H. Z. Fischer | Director | – | – | Jun 12, 2026 |
| Michael John Tomsicek | Director | 15,000 | 0.01% | Jun 12, 2026 |
| Andrew Saik | Director | – | – | Jun 12, 2026 |
| Lisa M. Giles | Director | – | – | Jun 12, 2026 |
| Debra K. Liebert | Director | 30,793 | 0.02% | Jul 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Oliveto President and CEO, Director | Apr 16, 2026 | Sale(10b5-1 plan) | −36,500 | $2.26 | $82.49K | 446,244 |
| Joseph Oliveto President and CEO, Director | Jan 26, 2026 | Option exercise | +66,600 | – | – | 517,267 |
| Joseph Oliveto President and CEO, Director | Jan 26, 2026 | Sale | −34,523 | $1.93 | $66.63K | 482,744 |
| Jeffrey Edward Nelson Chief Operating Officer | Jan 26, 2026 | Sale | −12,245 | $1.93 | $23.63K | 49,848 |
| Jeffrey Edward Nelson Chief Operating Officer | Jan 26, 2026 | Option exercise | +20,100 | – | – | 62,093 |
| Amit Hasija CFO & EVP of Corp. Development | Jan 26, 2026 | Option exercise | +20,100 | – | – | 112,093 |
| Amit Hasija CFO & EVP of Corp. Development | Jan 26, 2026 | Sale | −12,245 | $1.93 | $23.63K | 99,848 |
| Lorenz Muller Chief Commercial Officer | Jan 26, 2026 | Sale | −11,180 | $1.93 | $21.58K | 205,406 |
| Lorenz Muller Chief Commercial Officer | Jan 26, 2026 | Option exercise | +20,100 | – | – | 216,586 |
| David Bharucha Chief Medical Officer | Jan 26, 2026 | Option exercise | +20,100 | – | – | 125,426 |
| David Bharucha Chief Medical Officer | Jan 26, 2026 | Sale | −12,245 | $1.93 | $23.63K | 113,181 |
| Joseph Oliveto President and CEO, Director | Jan 8, 2026 | Sale(10b5-1 plan) | −43,000 | $2.25 | $96.75K | 303,721 |
| Joseph Oliveto President and CEO, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −500 | $2.25 | $1.13K | 346,721 |
| Joseph Oliveto President and CEO, Director | Dec 15, 2025 | Sale | −133,054 | $2.32 | $308.69K | 450,667 |
| Jeffrey Edward Nelson Chief Operating Officer | Dec 15, 2025 | Sale | −58,007 | $2.32 | $134.58K | 41,993 |
| Amit Hasija CFO & EVP of Corp. Development | Dec 15, 2025 | Sale | −58,007 | $2.32 | $134.58K | 91,993 |
| Lorenz Muller Chief Commercial Officer | Dec 15, 2025 | Sale | −53,566 | $2.32 | $124.27K | 196,486 |
| David Bharucha Chief Medical Officer | Dec 15, 2025 | Sale | −58,007 | $2.32 | $134.58K | 105,326 |
| Joseph Oliveto President and CEO, Director | Dec 12, 2025 | Award | +280,000 | – | – | 583,721 |
| Jeffrey Edward Nelson Chief Operating Officer | Dec 12, 2025 | Award | +100,000 | – | – | 100,000 |
| Amit Hasija CFO & EVP of Corp. Development | Dec 12, 2025 | Award | +100,000 | – | – | 150,000 |
| Lorenz Muller Chief Commercial Officer | Dec 12, 2025 | Award | +100,000 | – | – | 250,052 |
| David Bharucha Chief Medical Officer | Dec 12, 2025 | Award | +100,000 | – | – | 163,333 |
| Lorenz Muller Chief Commercial Officer | Dec 9, 2025 | Gift | −25,000 | – | – | 150,052 |
| Debra K. Liebert Director | Jul 11, 2025 | Award | +16,666 | – | – | 16,793 |
| Joseph C. Papa Director | Jul 11, 2025 | Award | +100,000 | – | – | 100,000 |
| Amit Hasija CFO & EVP of Corp. Development | Jul 11, 2025 | Award | +50,000 | – | – | 50,000 |
| Lorenz Muller Chief Commercial Officer | Jul 11, 2025 | Award | +66,666 | – | – | 175,052 |
| David Bharucha Chief Medical Officer | Jul 11, 2025 | Award | +53,333 | – | – | 63,333 |
| Robert James Wills Director | Jul 11, 2025 | Award | +50,000 | – | – | 65,000 |
| Joseph Oliveto President and CEO, Director | Jul 11, 2025 | Award | +66,666 | – | – | 347,221 |
| Roderick Wong 10% owner | Mar 22, 2023 | Other | −1,059,000 | – | – | 3,256,102 |
| David Bharucha Chief Medical Officer | Dec 5, 2022 | Buy | +7,000 | $4.69 | $32.83K | 10,000 |
| David Bharucha Chief Medical Officer | Dec 1, 2022 | Buy | +3,000 | $4.86 | $14.58K | 3,000 |
| Debra K. Liebert Director | Oct 21, 2022 | Buy | +4,000 | $5.26 | $21.04K | 4,000 |
| Richard C. Pasternak Director | Oct 20, 2022 | Buy | +10,000 | $5.20 | $52.00K | 10,000 |
| Debra K. Liebert Director | Oct 20, 2022 | Buy | +10,000 | $5.29 | $52.90K | 10,000 |
| Robert James Wills Director | Oct 19, 2022 | Buy | +15,000 | $4.93 | $73.95K | 15,000 |
| Michael John Tomsicek Director | Oct 19, 2022 | Buy | +15,000 | $5.32 | $79.80K | 15,000 |
| Debra K. Liebert Director | Sep 14, 2022 | Other | +127 | – | – | 127 |
| Rtw Investments, Lp 10% owner | Sep 7, 2022 | Sale | −1,557,346 | $8.71 | $13.56M | 4,315,102 |
| Rtw Investments, Lp 10% owner | Sep 7, 2022 | Buy | +1,557,346 | $8.71 | $13.56M | 4,315,102 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +8,016 | $1.12 | $8.98K | 8,016 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +45,072 | $1.54 | $69.41K | 53,088 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +22,870 | $1.54 | $35.22K | 75,958 |
| Paul F. Truex Director | May 31, 2022 | Option exercise | +822 | $2.66 | $2.19K | 76,780 |
| Paul F. Truex Director | May 31, 2022 | Buy | +5,000 | $5.60 | $28.00K | 81,780 |
| Lorenz Muller Chief Commercial Officer | Aug 26, 2020 | Option exercise | +5,700 | $1.54 | $8.78K | 108,386 |
| De Solidarite Des Travailleurs Du Quebec Fonds 10% owner | Jul 29, 2020 | Sale | −500,000 | $8.32 | $4.16M | 2,254,920 |
| De Solidarite Des Travailleurs Du Quebec Fonds 10% owner | Jul 28, 2020 | Sale | −19,863 | $8.10 | $160.89K | 2,754,920 |
| Lorenz Muller Chief Commercial Officer | Apr 3, 2020 | Option exercise | +32,528 | $1.54 | $50.09K | 84,643 |
| Lorenz Muller Chief Commercial Officer | Apr 3, 2020 | Option exercise | +18,043 | $1.54 | $27.79K | 102,686 |
| Rtw Investments, Lp 10% owner | Mar 19, 2020 | Buy | +5,870 | $10.87 | $63.81K | 4,315,102 |
| Rtw Investments, Lp 10% owner | Mar 18, 2020 | Buy | +2,705 | $10.36 | $28.02K | 4,309,232 |
| Rtw Investments, Lp 10% owner | Mar 2, 2020 | Buy | +78,263 | $18.95 | $1.48M | 4,306,527 |
| Roderick Wong 10% owner | Jan 13, 2020 | Buy | +270,000 | $16.25 | $4.39M | 4,228,264 |
| Rtw Investments, Lp 10% owner | Dec 31, 2019 | Buy | +21,438 | $15.50 | $332.29K | 3,958,264 |
| Rtw Investments, Lp 10% owner | Dec 30, 2019 | Buy | +1,333 | $15.48 | $20.63K | 3,936,826 |
| Joseph Oliveto President and CEO, Director | Dec 21, 2019 | Option exercise | +7,400 | $1.54 | $11.40K | 280,555 |
| Holdings A/S Novo 10% owner | Nov 25, 2019 | Sale | −240,000 | $16.00 | $3.84M | 2,434,470 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Oliveto Joseph Director, Officer | Apr 16, 2026 | 36,500 | $80.30K | Apr 16, 2026 | Previously Exercised Stock Options |
| Oliveto Joseph Director, Officer | Jan 8, 2026 | 79,500 | $170.93K | Jan 8, 2026 | Previously Exercised Stock Options |
| Oliveto Joseph Officer | Jan 7, 2026 | 500 | $1.03K | Jan 7, 2026 | Previously Exercised Stock Options |